WHO Issues Warning Over Severe Lack of Obesity Jabs

Fewer than 10% of patients eligible to benefit from obesity jabs such as Wegovy are able to get them, states the WHO as it issues its initial recommendations on the therapies.

Considering over a billion individuals worldwide now living with obesity, it is advocating for broader and more equitable access to GLP-1 medication.

Per projections, over two billion are projected to be living with obesity by 2030 unless action is taken.

"Our latest guidance recognises that obesity is a long-term condition that can be addressed with thorough and lifelong treatment," stated its chief Tedros Adhanom Ghebreyesus.

Substantial prices, constrained manufacturing, and supply-chain constraints are major hurdles to broad availability to the injections that can assist patients in reducing significant body mass, says the body.

GLP-1 Therapy Scarcity

Despite the current most favorable case, the manufacturing of GLP-1 therapies could only cover approximately 100 million people – less than 10% of the global need, per the WHO.

The advice calls on countries and companies to increase access, via approaches including licensing agreements.

Exclusive production rights on semaglutide – the primary ingredient of a leading brand – is scheduled to end in several countries in 2026.

The Way Obesity Jabs Operate

These medications mimick a natural hormone to slow digestion, reduce hunger and increase satiety so individuals consume fewer calories.

Individuals usually begin shedding pounds within a few weeks of starting on the once-weekly jabs.

Studies points to patients may put most of the weight back on a year later of halting the treatment, because their normal food cravings return.

Being carrying excess weight increases your chance for experiencing diseases, like diabetes, heart disease, stroke, and certain cancers.

Obesity concerns people in every country and was linked to millions of fatalities worldwide in 2024, as per the health agency.